Back-of-the-envelope calculations show that Serum Institute of India (SII) will lose revenues worth Rs 26.25 crore a month, while Bharat Biotech would lose to the tune of Rs 45 crore a month
New owners have to divest part of their stake of about 98 per cent in the firm, which re-listed in Mumbai in early November after emerging from bankruptcy
While big pharma has vehemently opposed India's move on compulsory licensing, even non-pharma influencers such as Bill Gates are against sharing vaccine technology without patenting
The government has given approval to four waitlisted firms under the Production Linked Incentive (PLI) scheme for domestic manufacturing of bulk drugs, an official statement said on Monday. The Department of Pharmaceuticals had launched the PLI scheme for promotion of domestic manufacturing of critical bulk drugs -- Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs). It envisages setting up greenfield plants in four different target segments with a total outlay of Rs 6,940 crore for the period 2020-21 to 2029-30. All the 215 applications received for the 36 products spread across the four target segments were considered and appraised and selected participants duly informed, the Ministry of Chemicals and Fertilizers said. Now, four waitlisted applicants who are otherwise eligible have been approved against slots vacated by withdrawal by companies which had earlier been granted approvals, the ministry said. The companies which have been gi
Founded by two IIT Bombay alumni, Mumbai based company Zeno Health is changing pharmaceutical industry.
During Q4FY21, firm launched Virafin to treat moderate infections in adult Covid-19 patients. Its ZyCoV-D plasmid DNA vaccine is at an advanced stage of Phase-3 trials
GST fitment panel has recommended a short-term rate cut on four Covid-19 related items
As Medlife discontinues operations, its users will move seamlessly to Pharmeasy, which will now serve 2 million households every month
Firms claim breakthrough with their RNA-marker tech which detects cancer even in stage zero
The ongoing April-June quarter should see strong growth due to low base of last year
The company already makes and markets antiviral drugs like remdesivir, favipiravir in India apart from importing and distributing Roche's tocilizumab (Actemra)
Net sales rise 6% to Rs 1,280 cr; API business expands by as much as 38%
States would have to fund procurement from their own budgets and bridge funding from the Centre is unlikely
Improving exports and a weak rupee could support profit boost
The stock has been underperforming recent months and trades at a discount to peers
Bharat Biotech is trying to ramp up capacities of Covaxin to 12 million doses per month by July, from the current 5 million doses per month
Company saw Form 483 with observations issued by US FDA for injectables plant in February
Consequent to the acquisition, Hemmo Pharmaceuticals Pvt Ltd would become a wholly-owned subsidiary of Piramal Pharma Ltd
Dhanuka Pharmaceuticals that took over the company almost a year ago, nursed it back to health from bankruptcy
In total, 215 applications have been received for the 36 products spread across the 4 target segments, the Ministry of Chemicals and Fertilizers said in the release